WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



Kattula Rao Vinay Rajan*, Pilla Sree Surya Durga Devi, Penugonda Vineela, Ravisankar Pasam, Haritha Allu, Prasad Reddy M


Vortioxetine is a novel atypical antidepressant indicated in the treatment of Major Depressive Disorder (MDD). Vortioxetine got approval by Food and Drug Administration (FDA) for its use in MDD in the USA in September 2013. It mainly acts by serotonin reuptake inhibition. Preclinical studies demonstrated that not only does vortioxetine have an antidepressant action but also that unlike many established antidepressants it may have cognition-enhancing effects and vortioxetine also elevates levels of the excitatory and inhibitory neurotransmitters such as serotonin, noradrenaline, dopamine, acetylcholine and histamine in specific areas of the rat brain. The most commonly noticed adverse events associated with vortioxetine treatment were nausea, headache, and dizziness. Sexual dysfunction and somnolence were also noticed in some patients. The recommended initial dose is 10mg once daily. . It should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus. This present review summarizes the pharmacology of vortioxetine.

Keywords: Vortioxetine, Major Depressive Disorder, serotonin syndrome.

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More